|
Instructions for Changes to Approval Details (Precautions for Use)
2006.02.13
|
|---|
|
[Notice] Instructions for Changes to Approval Details (Precautions for Use) of Non-Steroidal Anti-Inflammatory Drugs
Products impacted: Nimax Tablets (Nimesulide) Cnac Injection (Diclofenac Beta-Dimethylamino Ethanol) Taruming Tablets (Tarniflumate) Roxpine Tablets (Roxoprofen Sodium) For inquiries related to this notice: Responsible Department: Daehan New Pharm Development Division Contact: 02-3415-7857 |


Home